Neuropathic pain: Mechanisms, therapeutic approach, and interpretation of clinical trials

CONTINUUM Lifelong Learning in Neurology

Volumn 18, Issue 1, 2012, Pages 161-175

  Attal, Nadine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BACLOFEN; BOTULINUM TOXIN A; CANNABINOID; CAPSAICIN; CARBAMAZEPINE; DESIPRAMINE; DULOXETINE; ENALAPRIL; GABAPENTIN; IMIPRAMINE; LEVORPHANOL; LIDOCAINE; MACROGOL; METHADONE; MORPHINE; NORTRIPTYLINE; OXCARBAZEPINE; OXYCODONE; PARACETAMOL; PREGABALIN; SERTRALINE; TOPIRAMATE; TRAMADOL; VALACICLOVIR; VENLAFAXINE;

ADULT; AGED; ALLODYNIA; ANALGESIA; APPETITE; ASTHENIA; BEDTIME DOSAGE; BLURRED VISION; BURNING SENSATION; CANCER PAIN; CASE REPORT; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONSTIPATION; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; EVENING DOSAGE; FATIGUE; FEMALE; GAIT DISORDER; GASTROINTESTINAL DISEASE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOGONADISM; INJECTION SITE PAIN; INTERVERTEBRAL DISK HERNIA; IRRITABILITY; LIMB DYSESTHESIA; LOW BACK PAIN; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MEDICAL HISTORY; MONONEUROPATHY; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PAIN; PAIN ASSESSMENT; PARAPLEGIA; PERIPHERAL EDEMA; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; PHANTOM PAIN; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; POSTHERPETIC NEURALGIA; PRURITUS; PYRAMIDAL SIGN; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SCREENING; SEDATION; SEIZURE; SENSORY DYSFUNCTION; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP; SLEEP DISORDER; SOCIAL BEHAVIOR; SOMNOLENCE; SPASTICITY; SPINAL CORD STIMULATION; SPINE INJURY; SPORT; SWEATING; TRAFFIC ACCIDENT; TRANSCUTANEOUS NERVE STIMULATION; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

EID: 84856916597     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000411564.41709.2d     Document Type: Review

References (51)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-1635. (Pubitemid 351620320)
2. Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-387. (Pubitemid 351680253)
3. Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: the saga of clinicaltools. Pain 2011;152(3 suppl):S74-S83.
4. Attal N, Fermanian C, Fermanian J, et al. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 2008;138(2):343-353.
5. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9(8):807-819.
6. Dworkin RH, O'ConnorAB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132(3):237-251. (Pubitemid 350051570)
7. Attal N, Cruccu G, Baron R, et al; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113-e88.
8. Bril V, England J, Franklin GM, et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76(20):1758-1765.
9. Tan T, Barry P, Reken S, Baker M; Guideline Development Group. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 2010;340:c1079.
10. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150(3):573-581.
11. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23(1):175-184. (Pubitemid 46191681)
12. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized controlled trials across a range of doses. Diabetes Care 2008;31(7):1448-1454.
13. Wiffen PJ, McQuay HJ, EdwardsJE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005;20(3): CD005452.
14. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 2009;25(3):185-192.
15. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007; 18(2):CD004846.
16. Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009;25(7):1663-1676.
17. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev 2009;60(1): 267-277.
18. Simpson DM, Brown S, Tobias J; NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70(24):2305-2313.
19. Backonja M, Wallace MS, Blonsky ER, et al; NGX-4010 C116 Study Group. NGX-4010, a high concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7(12):1106-1112.
20. Backonja MM, Malan TP, Vanhove GF, Tobias JK; C102/106 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med 2010;11(4):600-608.
21. Simpson DM, Gazda S, Brown S, et al; NGX-4010 C118 Study Group. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patientswith peripheral neuropathic pain. J Pain Symptom Manage 2010;39(6):1053-1064.
22. Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010;11(6):579-587.
23. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293(24):3043-3052. (Pubitemid 40965075)
24. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005; 7(5):R1046-R1051.
25. Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain 2007;23(4): 287-299. (Pubitemid 46650020)
26. Upadhyay J, Maleki N, Potter J, et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain 2010; 133(pt 7):2098-2114.
27. Crofford LJ. Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nat Rev Rheumatol 2010;6(4):191-197.
28. Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalin in patientswith central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008;136(1-2): 150-157. (Pubitemid 351491377)
29. Kim JS, Bashford G, Murphy TK, et al. Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain 2011;152(5): 1018-1023.
30. Vranken J, Hollmann MW, van der Vegt MH, et al. Duloxetine in patientswith central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2011;152(2): 267-273.
31. Gordh TE, Stubhaug A, Jensen TS, et al. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain 2008;138(2):255-266.
32. van Seventer R, Bach FW, Toth CC, et al. Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. Eur J Neurol 2010;17(8):1082-1089.
33. Baron R, Freynhagen R, Tölle T, et al; A008107 Investigators. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with lumbosacral radiculopathy. Pain 2010; 150(3):420-427.
34. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007; 130(1-2):66-75. (Pubitemid 46850784)
35. Gilron I, Baley JM, Tu D, et al. Nortritpyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374(9697): 1252-1261.
36. Bansal D, Bhansali A, Hota D, et al. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009;26(10): 1019-1026.
37. Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med 2007;24(4):377-383. (Pubitemid 46452398)
38. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352(13): 1324-1334. (Pubitemid 40411499)
39. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12(6):804-813.
40. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64(3):274-283.
41. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009;72(17):1473- 1478.
42. Xiao L, Mackey S, Hui H, et al. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med 2010; 11(12):1827-1833.
43. Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 2006;4(3):239-257.
44. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 2007;14(9):952-970. (Pubitemid 47300786)
45. Lefaucheur JP, DrouotX, Cunin P, et al. Motor cortex stimulation for the treatment of refractory peripheral neuropathic pain. Brain 2009;132(pt 6):1463-1471.
46. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology 2008; 70(4):263-272. (Pubitemid 351156805)
47. Haythornthwaite JA, Clark MR, Pappagallo M, Raja SN. Pain coping strategies play a role in the persistence of pain in post-herpetic neuralgia. Pain 2003;106(3):453-460. (Pubitemid 37505894)
48. Sullivan MJ, Lynch ME, ClarkAJ. Dimensions of catastrophic thinking associated with pain experience and disability in patients with neuropathic pain conditions. Pain 2005; 113(3):310-315. (Pubitemid 40127512)
49. Bouhassira D, Attal N. Novel strategies for neuropathic pain. In: Villanueva L, Dickenson A, Ollat H, eds. The pain system in normal and pathological states: a primer for clinicians. Seattle: IASP Press, 2004.
50. Attal N, Bouhassira D, Baron R, et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain2011;15(5):441-443.
51. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152(1):14-27.